Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.
This study has been completed.
Study NCT00210834 Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received on September 13, 2005. Last Updated on June 8, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
More general conditions related to this trial
Interventions listed in this trial
More general drug interventions related to this trial
Sponsors listed in this trial
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ortho Biotech Products, L.P.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers